Back to top
more

Molecular Templates (MTEM)

(Delayed Data from NSDQ)

$1.70 USD

1.70
2,374

-0.03 (-1.73%)

Updated Apr 30, 2024 09:30 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Molecular Templates Inc. (MTEM) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -282.14% and -89.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Molecular Templates Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Molecular Templates

Catalyst's (CPRX) Q4 Earnings Miss Estimates, Revenues Meet

by Zacks Equity Research

Catalyst's (CPRX) earnings lag estimates in the fourth quarter. Revenues match the same.

Sejuti Banerjea headshot

7 Great Stocks for a Small Budget

by Sejuti Banerjea

Take advantage of panic selling with these 7 cheap stocks.

Will Molecular Templates Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Molecular Templates.

Analysts Estimate Molecular Templates (MTEM) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Molecular Templates (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Molecular Templates to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Molecular Templates.

Will Molecular Templates (MTEM) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Molecular Templates (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy

Kinjel Shah headshot

Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy

by Kinjel Shah

Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.

Will Molecular Templates Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Molecular Templates.

Molecular Templates Surges 50%, Inks Cancer Deal With Takeda

by Zacks Equity Research

Molecular Templates (MTEM) signs a collaborative contract with Japan's Takeda for jointly developing CD38-targeted engineered toxin antibodies to treat multiple myeloma. The stock soars past 50%.

    Moving Average Crossover Alert: Molecular Templates Inc. (MTEM)

    by Zacks Equity Research

    Moving Average Crossover Alert: Molecular Templates Inc. (MTEM)